Similar articles for PMID: 25199774

Year	Number of Results
1999	1
2003	1
2004	2
2005	3
2006	1
2007	6
2008	4
2009	6
2010	8
2011	9
2012	10
2013	5
2014	6
2015	12
2016	13
2017	13
2018	10
2019	7
2020	5
2021	1
2022	3
2023	2
2024	0

1

Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.

Jung DS, Tverdek FP, Kontoyiannis DP. Jung DS, et al. Antimicrob Agents Chemother. 2014 Nov;58(11):6993-5. doi: 10.1128/AAC.04035-14. Epub 2014 Sep 8. Antimicrob Agents Chemother. 2014. PMID: 25199774 Free PMC article.

2

Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.

Krishna G, Ma L, Martinho M, O'Mara E. Krishna G, et al. Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201. doi: 10.1128/AAC.00222-12. Epub 2012 May 21. Antimicrob Agents Chemother. 2012. PMID: 22615291 Free PMC article. Clinical Trial.

3

Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.

Döring M, Cabanillas Stanchi KM, Queudeville M, Feucht J, Blaeschke F, Schlegel P, Feuchtinger T, Lang P, Müller I, Handgretinger R, Heinz WJ. Döring M, et al. J Cancer Res Clin Oncol. 2017 Jul;143(7):1281-1292. doi: 10.1007/s00432-017-2369-7. Epub 2017 Mar 3. J Cancer Res Clin Oncol. 2017. PMID: 28258343 Clinical Trial.

4

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, Chandrasekar P, Langston A, Perfect J, Ma L, van Iersel ML, Connelly N, Kartsonis N, Waskin H. Duarte RF, et al. Antimicrob Agents Chemother. 2014 Oct;58(10):5758-65. doi: 10.1128/AAC.03050-14. Epub 2014 Jul 21. Antimicrob Agents Chemother. 2014. PMID: 25049247 Free PMC article. Clinical Trial.

5

Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.

Vanstraelen K, Prattes J, Maertens J, Lagrou K, Schoemans H, Peersman N, Vermeersch P, Theunissen K, Mols R, Augustijns P, Annaert P, Hoenigl M, Spriet I. Vanstraelen K, et al. Eur J Clin Pharmacol. 2016 Aug;72(8):953-63. doi: 10.1007/s00228-016-2057-6. Epub 2016 Apr 11. Eur J Clin Pharmacol. 2016. PMID: 27066958

6

Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.

Gautier-Veyret E, Bolcato L, Roustit M, Weiss S, Tonini J, Brenier-Pinchart MP, Cornet M, Thiebaut-Bertrand A, Stanke-Labesque F. Gautier-Veyret E, et al. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00484-19. doi: 10.1128/AAC.00484-19. Print 2019 Oct. Antimicrob Agents Chemother. 2019. PMID: 31358587 Free PMC article.

7

Posaconazole delayed-release tablets in paediatric haematology-oncology patients.

Mauro M, Colombini A, Perruccio K, Zama D, D'Amico MR, Calore E, Carraro F, Muggeo P, Tridello G, Baretta V, Cesaro S. Mauro M, et al. Mycoses. 2020 Jun;63(6):604-609. doi: 10.1111/myc.13084. Epub 2020 Apr 15. Mycoses. 2020. PMID: 32246512

8

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.

Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. Krishna G, et al. J Antimicrob Chemother. 2012 Nov;67(11):2725-30. doi: 10.1093/jac/dks268. Epub 2012 Jul 24. J Antimicrob Chemother. 2012. PMID: 22833639 Free PMC article. Clinical Trial.

9

Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.

Durani U, Tosh PK, Barreto JN, Estes LL, Jannetto PJ, Tande AJ. Durani U, et al. Antimicrob Agents Chemother. 2015 Aug;59(8):4914-8. doi: 10.1128/AAC.00496-15. Epub 2015 Jun 8. Antimicrob Agents Chemother. 2015. PMID: 26055378 Free PMC article.

10

Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.

Liebenstein TK, Widmer KM, Fallon MJ. Liebenstein TK, et al. J Oncol Pharm Pract. 2018 Dec;24(8):599-603. doi: 10.1177/1078155217722405. Epub 2017 Aug 2. J Oncol Pharm Pract. 2018. PMID: 28768441

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

105 results

Results by year